News Lundbeck Nasdaq Copenhagen

Equities

LUN

DK0061804697

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2024-07-12 am EDT			5-day change	1st Jan Change
34.95 ^DKK	-1.55%		+2.19%	+1.19%

Jun. 26	Otsuka and Lundbeck's PTSD Treatment Moves Forward as FDA Accepts New Drug Application	MT
Jun. 25	US FDA Accepts Lundbeck, Otsuka's New Drug Application for PTSD Combo Treatment	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Otsuka and Lundbeck's PTSD Treatment Moves Forward as FDA Accepts New Drug Application	Jun. 25	MT
US FDA Accepts Lundbeck, Otsuka's New Drug Application for PTSD Combo Treatment	Jun. 25	MT
Lundbeck and Otsuka announce FDA acceptance of sNDA filing for brexpiprazole in combination with sertraline for the treatment of adults with post-traumatic stress disorder (PTSD)	Jun. 25	AQ
Lundbeck and Otsuka Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder	Jun. 25	CI
Lundbeck broadens focus on neurohormonal dysfunctions with new Cushing's disease trial	Jun. 19	AQ
H. Lundbeck A/S Expands Focus on Neurohormonal Dysfunctions with New Cushing's Disease Trial	Jun. 19	CI
Lundbeck presents innovative first in human trial design of Lu AG13909 for potential treatment of congenital adrenal hyperplasia	Jun. 03	AQ
Lundbeck Presents Innovative First in Human Trial Design of Lu AG13909 for Potential Treatment of Congenital Adrenal Hyperplasia	Jun. 03	CI
H LUNDBECK : Q1 beat adds momentum to the recent share price rally	May. 15
Transcript : H. Lundbeck A/S, Q1 2024 Earnings Call, May 15, 2024	May. 15
Lundbeck grows strategic brands by +17% CER reaching total revenue of DKK 5.3 billion in the first quarter of 2024	May. 15	AQ
H. Lundbeck A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15	CI
H. Lundbeck A/S Provides Earnings Guidance for the Year 2024	May. 15	CI
H LUNDBECK : Lundbeck is well-poised to sail through the transition period	May. 13
Maria Alfaiate appointed new Executive Vice President Commercial and Corporate Strategy at Lundbeck	May. 13	AQ
H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024	May. 13	CI
H. Lundbeck, Otsuka Pharmaceutical Seek US FDA Nod for PTSD Combination Therapy	Apr. 09	MT
Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD	Apr. 09	AQ
Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD	Apr. 09	CI
Lundbeck : Articles of Association	Apr. 02	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

H LUNDBECK : Q1 beat adds momentum to the recent share price rally

May 15, 2024 at 12:20 pm EDT